{
  "id": 19414129,
  "title": "GLP-1 drugs carry risk of rare but serious eye condition – a physician studying these medicines explains the potential side effect",
  "url": "https://urgent.news/2026/11/10/glp-1-drugs-carry-risk-of-rare-but-serious-eye-condition-a-physician",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-10T23:07:25.000Z",
  "source": {
    "name": "The Conversation",
    "slug": "the-conversation",
    "url": "https://theconversation.com/glp-1-drugs-carry-risk-of-rare-but-serious-eye-condition-a-physician-studying-these-medicines-explains-the-potential-side-effect-296237"
  },
  "original_language": "en",
  "account": "Millions of people worldwide take GLP-1 medications to treat conditions like diabetes and obesity. The U.S. Food and Drug Administration (FDA) has now issued a warning label regarding a potential link to a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION), which can cause vision loss. As a clinician and epidemiologist who has studied GLP-1 drugs, I have contributed to one of the studies identifying the connection between these medications and NAION. While the risk is low, it's important for patients to be aware of this potential side effect. NAION is an injury to the optic nerve due to a sudden reduction in blood flow, resulting in sudden, painless blurry vision, dark patches, partial loss of vision, or even blindness. These symptoms often appear in the morning when blood pressure is lower. The FDA's warning is based on data showing a real but low risk of NAION for people taking GLP-1 medications. The increased risk compares to a placebo or different medication, translating to 2.6 extra cases per 100,000 patients on GLP-1 drugs. This risk is consistent across various studies and medications within the GLP-1 class. While the risk is small, it is still important for patients to be aware of this potential outcome when using GLP-1 drugs for FDA-approved conditions.",
  "summary": "Doctors often call the condition a stroke of the eye – and though the risk is small, patients should know the symptoms and seek immediate treatment if they occur.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 4,
    "also_reported_by": [
      {
        "outlet": "Free Malaysia Today",
        "title": "US FDA requires GLP-1 drugmakers to add warning about potential eye risk",
        "url": "https://urgent.news/2026/11/10/us-fda-requires-glp-1-drugmakers-to-add-warning-about-potential-eye",
        "published": "2026-11-10T05:15:47.000Z"
      },
      {
        "outlet": "Live Mint",
        "title": "FDA flags potential vision loss risk linked to GLP-1 drugs: What users of weight-loss medications should know",
        "url": "https://urgent.news/2026/11/10/fda-flags-potential-vision-loss-risk-linked-to-glp-1-drugs-what-users",
        "published": "2026-11-10T10:18:26.000Z"
      },
      {
        "outlet": "STAT News",
        "title": "STAT+: GLP-1s are given an FDA warning for rare eye condition risk",
        "url": "https://urgent.news/2026/11/10/stat-glp-1s-are-given-an-fda-warning-for-rare-eye-condition-risk",
        "published": "2026-11-10T14:38:29.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}